Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 33, 2016
Previous Article Next Article

The Platin-X series: activation, targeting, and delivery

Author affiliations


Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the “magic bullet” which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.

Graphical abstract: The Platin-X series: activation, targeting, and delivery

Back to tab navigation

Publication details

The article was received on 03 May 2016, accepted on 09 Jul 2016 and first published on 11 Jul 2016

Article type: Perspective
DOI: 10.1039/C6DT01738J
Citation: Dalton Trans., 2016,45, 12992-13004

  •   Request permissions

    The Platin-X series: activation, targeting, and delivery

    U. Basu, B. Banik, R. Wen, R. K. Pathak and S. Dhar, Dalton Trans., 2016, 45, 12992
    DOI: 10.1039/C6DT01738J

Search articles by author